글로벌 약물 장치 조합 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

약물 장치 조합 시장 분석

약물-장치 조합 시장은 약물 전달 기술의 발전과 심혈관 질환, 당뇨병, 암과 같은 만성 질환의 유병률 증가로 수요가 증가하면서 강력한 성장을 경험하고 있습니다. 용도를 다한 후 용해되는 생체흡수성 스텐트와 통증 없는 표적 전달을 제공하는 미세바늘 약물 패치와 같은 주요 혁신은 치료 정밀도와 환자 결과를 크게 개선하고 있습니다. 특히 종양학 분야에서 개인화된 의학의 증가와 약물을 이식형 장치와 통합하는 조합 요법의 사용은 시장 확장을 계속 촉진하고 있습니다. 미국 FDA의 조합 제품 정책 위원회와 유럽 의약품 기관(EMA)의 조합 제품에 대한 맞춤형 경로와 같은 규제 기관은 승인 절차를 가속화하여 새로운 기술의 시장 진입을 더 빠르게 할 수 있도록 하고 있습니다.

약물 장치 조합 시장 규모

글로벌 약물 장치 조합 시장 규모는 2023년에 156억 3천만 달러로 평가되었으며, 2031년까지 340억 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 10.20%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

약물 장치 조합 시장 동향

“ 스마트 약물 전달 시스템 사용 증가”

Propeller Health의 연결된 흡입기와 Tandem Diabetes의 tX2 인슐린 펌프와 같은 트렌드 스마트 약물 전달 시스템은 약물 투여와 실시간 디지털 추적을 통합하여 만성 질환 관리에 혁명을 일으키고 있습니다. 이러한 장치는 환자가 약물 사용과 건강 데이터를 모니터링할 수 있는 앱에 연결되어 환자와 의료 제공자 모두에게 귀중한 피드백을 제공합니다. 예를 들어, Propeller의 흡입기는 천식 약물 사용을 추적하고 사용자에게 환경적 트리거를 경고하여 준수와 관리를 개선합니다. 마찬가지로 tX2 인슐린 펌프는 지속적인 포도당 데이터를 기반으로 인슐린 투여를 조정하여 당뇨병 환자에게 보다 정확하고 개인화된 치료를 보장합니다. 이러한 기술 중심적 접근 방식은 사전 예방적 질병 관리를 촉진하여 환자 결과를 개선하고 입원을 줄이고 있습니다.

보고서 범위 및 약물 장치 조합 시장 세분화   

Drug Device Combination Market Definition

A drug-device combination is a product that integrates a pharmaceutical drug with a medical device, designed to deliver the drug to the patient in a controlled and effective manner. Such combinations can enhance the therapeutic benefits of the drug while providing convenience and precision in administration. For instance, Insulin pumps, which deliver insulin to manage diabetes, and inhalers equipped with sensors that track medication use. The integration of the drug and device components ensures that the medication is administered correctly and that the device supports the intended therapeutic outcomes.

Drug Device Combination Market Dynamics

Drivers

• Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases, such as cardiovascular conditions, diabetes, and cancer, is a major driver of the drug-device combination market, as these conditions require long-term management and precise treatment. For instance, according to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, responsible for an estimated 17.90 million deaths annually. Such statistics underscore the need for innovative treatment solutions. Drug-device combinations, such as drug-eluting stents for heart disease and insulin pumps for diabetes, offer targeted and sustained drug delivery, enhancing treatment efficacy and improving patient compliance. The growing burden of such chronic conditions is pushing healthcare providers and patients to seek more effective, integrated solutions, thereby boosting demand for drug-device combinations that offer both convenience and improved health outcomes.

• Growth of Personalized Medicine

The growth of personalized medicine is significantly driving the development of tailored drug-device combinations, especially in oncology. Such shift is exemplified by the use of personalized drug-delivery systems that cater to individual patient profiles, enhancing treatment precision and efficacy. For instance, The Kymriah therapy by Novartis, which involves genetically modifying a patient’s own T cells to target cancer cells more effectively. Such therapy is paired with specialized infusion devices to ensure precise administration and monitoring. Additionally, the integration of advanced biomarker profiling and genetic testing helps in creating bespoke treatment plans, which are tailored to the unique genetic and molecular characteristics of each patient's cancer. Such approach not only improves the effectiveness of treatments but also minimizes adverse effects, setting a new standard for personalized oncology care. As a result, the personalized medicine trend is driving significant advancements in drug-device combinations, paving the way for more targeted and effective cancer therapies.

Opportunities

• Rise in Ageing Population

The aging global population is significantly boosting the demand for long-term disease management solutions, and drug-device combinations are well-suited to address this need. According to the United Nations, the number of people aged 60 and older is projected to reach 2.1 billion by 2050, representing a substantial increase in the prevalence of age-related chronic conditions. Apparent demographic shift is driving demand for innovative products such as continuous glucose monitoring systems and advanced pacemakers. For instance, the Dexcom G6 continuous glucose monitoring system, which combines a wearable sensor with real-time glucose tracking, has become increasingly popular among older adults managing diabetes. Such drug-device combinations not only improve the quality of life for aging individuals but also offer practical solutions for managing chronic conditions over the long term.

• Rising Demand for Minimally Invasive Procedures

The rising demand for minimally invasive procedures is profoundly influencing the drug-device combination market, as these products provide less invasive alternatives that facilitate quicker recovery and shorter hospital stays. Minimally invasive techniques, such as those involving drug-eluting stents and advanced endoscopic systems, are increasingly preferred for their ability to reduce surgical trauma and improve patient outcomes. For instance, drug-eluting stents, which release medication to prevent the re-narrowing of arteries, have been shown to decrease the need for repeat procedures and minimize recovery time. Such growing preference for minimally invasive approaches not only enhances patient comfort and safety but also contributes to overall healthcare efficiency, driving the continued expansion and innovation within the drug-device combination market.

Restraints/Challenges

• Complex Intellectual Property Rights

Intellectual property concerns are particularly significant in the drug-device combination market, where protecting innovations involves navigating a complex landscape of patents and potential infringement disputes. For instance, Medtronic’s recent approval of its MiniMed 780G insulin pump, a drug-device combination, highlights the challenges in securing IP. The company has invested heavily in patenting its technology to safeguard its innovations against competitors. However, patent disputes are common, as evidenced by a 2023 lawsuit where a rival company, Tandem Diabetes, challenged Medtronic’s patent claims, alleging that their technology infringed on existing patents. Such disputes can lead to costly legal battles and potentially hinder market entry for new players.

• Rising Supply chain complexities

Supply chain complexities are a significant challenge in the drug-device combination market due to the need to coordinate multiple suppliers and manufacturers. For instance, the production of insulin delivery systems, such as the Tandem Diabetes tX2 insulin pump, involves sourcing components from various global suppliers, including electronic components, drug reservoirs, and infusion sets. Managing this intricate supply chain is critical to ensure timely delivery and product quality. In 2022, Tandem faced disruptions when a key supplier for electronic components experienced delays, impacting the production schedule and leading to shortages in the market. Such situations highlighted the vulnerability of the supply chain in the drug-device sector, where any delay or disruption can have cascading effects on manufacturing timelines, product availability, and ultimately, patient care. Consequently impeding the drug-device combination market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Drug Device Combination Market Scope

The market is segmented on the basis of products, application types, end users, and distribution channels. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Auto-Injector
• Infusion Pumps
  • Implantable Infusion Pumps
  • Ambulatory Infusion Pumps
• Photosensitizers
• Woundcare Combination Products
• Transdermal Patches
• Microneedle Patch
• Digital Pill
• Smart Inhaler
  • Metered Dose Inhalers
  • Dry Powder Inhalers
  • Nebulizers
• Drug Delivery Hydrogels
• Drug-Eluting Lens
  • Coronary Stents
  • Peripheral Vascular Stents
• Others
  • Intraocular Implants
  • Drug Eluting Beads

Application Type

• Orthopedic Diseases
• Respiratory Diseases
• Diabetes
• Oncology
• Cardiovascular Diseases
• Others

End User

• Clinics
• Hospitals
• Home Care Settings
• Ambulatory Care Centers
• Others

Distribution Channel

• Direct Tender
• Retail Sales
• Others

Drug Device Combination Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, products, application types, end users, and distribution channels as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to capture a significant share of the global drug-device combination market. This is due to the region's strong healthcare infrastructure, increased awareness of drug-device combinations, and their widespread use. Additionally, the high prevalence of chronic conditions further drives market growth, positioning North America as a major force in this advancing healthcare sector.

The Asia-Pacific region is expected to be the fastest-growing market in the global drug-device combination sector from 2024 to 2031. This rapid growth is driven by its large population, increasing adoption of advanced technologies, rising demand for personalized medicine, and a higher incidence of chronic diseases. As a result, Asia-Pacific is becoming a crucial player in the evolving field of drug-device combination products.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Drug Device Combination Market Share

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 운영되는 약물 장치 조합 시장 리더는 다음과 같습니다.

• 메드트로닉(아일랜드)
• 짐머 바이오멧(미국)
• 암젠 주식회사(미국)
• Mediprint Apparatebau GmbH(독일)
• 프로펠러 헬스(미국)
• BD(미국)
• CosMED Pharmaceutical Co., Ltd (일본)
• 마이크론 바이오메디컬 주식회사(미국)
• Findair Sp. z oo (폴란드)
• MetP Pharma AG(스위스)
• Sonceboz SA(스위스)
• 에이탄 메디컬(이스라엘)
• Vaxess Technologies Inc. (미국)
• GSK plc (영국)
• Bayer AG(독일)
• 나노패스(이스라엘)
• 센시리온 AG(스위스)
• Janssen Global Services, LLC(미국)
• 인슐렛 코퍼레이션(미국)
• 테라젝트(미국)
• 오츠카 아메리카 제약 주식회사(미국)
• EOFLOW CO., LTD. (한국)
• CGbio(한국)

약물 장치 조합 시장의 최신 개발

• 2022년 12월, 테루모 주식회사는 교와기린 주식회사와 협력하여 개발한 약물-의료기기 복합제품인 G-Lasta 피하주사 3.6mg BodyPod를 출시했습니다. 이 제품은 일본 후생노동성(MHLW)의 승인을 받았습니다.
• 2024년 3월, SHL은 스위스 CDMO ten23과 협력하여 무균 약물-장치 조합 제품이 필요한 회사에 포괄적인 서비스를 제공했습니다. 이 협력은 ten23의 계약 개발 및 제조 전문성과 SHL Medical의 고급 자동 주입 장치 기술을 결합합니다.

SKU-50708